Survival improvements were noted in brain and nervous system cancers, colorectal cancers, and lung cancer.
About 31% of the articles analyzed contained information classified as harmful.
Surgery was an independent predictor of overall survival.
Researchers sought to determine whether cryopreservation of unrelated donor hematopoietic stem cells would affect outcomes in patients who underwent HSCT since the COVID-19 pandemic.
When researchers combined clinical features with BRAF mutant allele fraction, patients could be divided into 3 risk groups that were significantly associated with survival.
The results suggest a link, but more research is needed.
Nab-paclitaxel was associated with an improvement in long-term overall survival.
The results led to another approved indication for pembrolizumab.
The association was observed with colon cancer but not rectal cancer.
The median duration of response was 35.7 weeks with iberdomide, bortezomib, and dexamethasone compared with not reached in patients who received iberdomide, daratumumab, and dexamethasone or iberdomide, bortezomib, and carfilzomib
